[1] Nadim M K, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis[J]. N Engl J Med,2023,388(8):733-745.
[2] Cullaro G, Kanduri S R, Velez J C Q. Acute kidney injury in patients with liver disease[J]. Clin J Am Soc Nephrol,2022(11):1674-1684.
[3] Ruiz-del-Arbol L, Monescillo A, Arocena C,et al. Circulatory function and hepatorenal syndrome in cirrhosis[J]. Hepatology,2005,42(2):439-447.
[4] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy[J]. J Hepatol,2020,72(3):558-577.
[5] Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis[J].Gut,2007,56(9):1310-1318.
[6] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites[J]. Gut,2015,64(4):531-537.
[7] Cullaro G, Rubin J B, Fortune B E, et al. Association between kidney dysfunction types and mortality among hospitalized patients with cirrhosis[J]. Dig Dis Sci, 2022,67(7):3426-3435.
[8] Patidar K R, Kang L, Bajaj J S, et al. Fractional excretion of urea: a simple tool for the differential diagnosis of acute kidney injury in cirrhosis[J]. Hepatology,2018,68(1):224-233.
[9] Alletretti A S. NGAL in AKI and cirrhosis—ready for prime time? [J]Hepatol,2023,77(5):1472-1474.
[10] Kulkarni A V, Arab J P, Premkumar M, et al.Terlipressin has stood the test of time: clinical overview in 2020 and future perspectives[J]. Liver Int,2020,40(12):2888-2905.
[11] Sanyal A J, Boyer T, Garcia-Tsao G,et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome[J]. Gastroenterology,2008,134(5):1360-1368.
[12] Boyer T D, Sanyal A J, Wong F,et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1[J]. Gastroenterology,2016,150(7):1579-1589.
[13] Wong F,Pappas S C, Curry M P,et al.Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome[J].N Engl J Med,2021,384(9):818-828.
[14] Patidar K R, Piano S, Cullaro G, et al.Recent advances in the management of hepatorenal syndrome:a US perspective[J].Clin Gastroenterol Hepatol,2023,21(4):897-901.e1.
[15] Cavallin M, Piano S, Romano A,et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study[J]. Hepatology,2016,63(3):983-992.
[16] Velez J C Q, Karakala N, Tayebi K, et al. Responsiveness to vasoconstrictor therapy in hepatorenal syndrome type 1[J]. Kidney360,2023,4(4):e448-e456.
[17] Sanyal A J, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind,placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome[J]. Gastroenterology,2008,134(5):1360-1368.
[18] Bajaj J S, O′Leary J G, Lai J C, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol. 2022;117:225-252.
[19] Biggins S W, Angeli P, Garcia-Tsao G,et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology,2021,74(2):1014-1048.
[20] Allegretti A S, Patidar K R, Ma A T,et al.From past to present to future:terlipressin and hepatorenal syndrome-acute kidney injury[J]. Hepatology,2025,81(6):1878-1897. |
